Skip to main content

Table 1 Baseline Characteristics of the 11 Patients Enrolled in the Study

From: First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Characteristic

Patients

n

%

Age, years

Median (range)

65 (35–79)

–

Sex

Male

8

73

 

Female

3

27

ECOG performance status

0

11

100

Cancer types

Gastric or gastro-esophageal

6

55

 

Colorectal

4

36

 

Esophageal

1

9

 

Pancreas

1

9

Microsatellite instability status

Microsatellite stable

9

82

 

Unknown

2

18

Previous treatment line

Median (range)

5 (2–11)

–

Previous anti-PD1/PDL1

Yes

4

36

Metastatic sites

Lymph node

8

73

 

Lung

5

45

 

Liver

4

36

  1. ECOG Eastern Cooperative Oncology Group